Scinai Immunotherapeutics (SCNI) Equity Ratio (2018 - 2025)

Scinai Immunotherapeutics has disclosed Equity Ratio across 8 years of filings, most recently posting 0.0 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.0, down 99.94% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.0 (down 99.94% YoY), and the FY2025 annual result was 0.0, down 99.94% from the prior year.
• Equity Ratio came in at 0.0 for Q4 2025 at Scinai Immunotherapeutics, down from 0.74 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 35.43 in Q3 2022 to a low of 0.26 in Q4 2023.
• The 5-year median for Equity Ratio is 0.02 (2021), against an average of 4.47.
• Peak annual rise in Equity Ratio reached 68499.63% in 2022, while the deepest fall reached 312.13% in 2022.
• Scinai Immunotherapeutics' Equity Ratio stood at 0.03 in 2021, then tumbled by 312.13% to 0.07 in 2022, then tumbled by 302.17% to 0.26 in 2023, then soared by 383.7% to 0.74 in 2024, then sank by 99.94% to 0.0 in 2025.
• The last three Equity Ratio figures came in at 0.0 (Q4 2025), 0.74 (Q4 2024), and 0.26 (Q4 2023), per Business Quant data.